Our systematic review demonstrates that GLP-1 receptor agonists (GLP-1 RAs), including semaglutide, liraglutide, tirzepatide, and exenatide, offer sustained efficacy in weight management, with consistent improvements in glycemic control among patients with obesity or overweight. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.